Breaking News

Opinion: Subscription pricing could work with HIV prevention drugs

April 3, 2026
Pharmalot Columnist, Senior Writer
Syringes filled with the HIV prevention drug lenacapavir.
Ihsaan Haffejee / AFP via Getty Images

Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs

The breakthrough HIV prevention injection lenacapavir is particularly well suited for subscription pricing.

By Michael Rose


Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine

With peptides like BPC-157, we are seeing 'the wholesale substitution of consumer enthusiasm for clinical evidence.'

By Vikas Patel


Biotech investors' plea to Trump, and a busy M&A week

STAT reporters discuss why an investor-patient coalition sent a letter to President Trump asking for change at the FDA.

By Elaine Chen, Adam Feuerstein, and Allison DeAngelis



Alex Hogan/STAT

STAT+ | Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

By Ed Silverman


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments